Overview

A Study of Bemarituzumab Monotherapy and Docetaxel Combination in Participants With Squamous Non-small-cell Lung Cancer (SqNSCLC) With Fibroblast Growth Factor Receptor Isoform 2b (FGFR2b) Overexpression

Status:
Not yet recruiting

Trial end date:
2025-02-16

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and in combination with docetaxel, and to determine the recommended Phase 3 dose of bemarituzumab monotherapy and in combination with docetaxel.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Bemarituzumab
Docetaxel